M

    Madrigal Pharmaceuticals Inc (MDGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $533.12
    -13.54 (-2.48%)

    Market Cap: $12.34B

    Last updated: Sep 10, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -14.13%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.09
    Range$-1.38 - $-0.56
    4 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.61+43.9%
    60d ago$-1.03+5.0%
    30d ago$-1.03+5.0%
    7d ago$-1.03+5.0%
    Current$-1.09
    Revenue Consensus
    $405M
    Range$385M - $425M
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.97
    Range$0.08 - $2.55
    4 analysts
    Revenue Consensus
    $468M
    Range$420M - $521M
    16 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.97---
    Sep 26EST
    		-$-1.09---
    Jun 26
    Reported Jul 30
    		$-1.99$-2.55+21.96%Beat-4.7%
    Mar 26
    Reported May 6
    		$-1.38N/A+66.67%Beat+58.4%
    Dec 25
    Reported Feb 19
    		$-2.57$-0.60-325.57%Miss+5.2%
    Sep 25
    Reported Nov 4
    		$-4.96$-1.99-149.25%Miss-0.8%
    Jun 25
    Reported Aug 5
    		$-1.90$-3.53+46.18%Beat+73.2%
    Mar 25
    Reported May 1
    		$-3.32$-3.79+12.40%Beat+55.0%
    Dec 24
    Reported Feb 26
    		$-2.71$-4.12+34.30%Beat+52.3%
    Sep 24
    Reported Oct 31
    		$-4.92$-6.91+28.80%Beat+7.9%
    Jun 24
    Reported Aug 7
    		$-7.10$-7.66+7.31%Beat-51.4%
    Mar 24
    Reported May 7
    		$-7.38$-6.28-17.52%Miss-74.5%
    Dec 23
    Reported Feb 28
    		$-5.68$-5.34-6.37%Miss-14.1%
    Sep 23
    Reported Nov 6
    		$-5.34$-4.93-8.32%Miss-12.4%
    Jun 23
    Reported Aug 8
    		$-4.69$-4.54-3.30%Miss-13.3%
    Mar 23
    Reported May 9
    		$-4.23$-4.94+14.37%Beat-25.9%
    Dec 22
    Reported Feb 23
    		$-4.98$-4.61-8.03%Miss-31.7%
    Sep 22
    Reported Nov 3
    		$-4.75$-4.18-13.64%Miss-25.3%
    Jun 22
    Reported Aug 4
    		$-4.14$-3.64-13.74%Miss-11.3%
    Mar 22
    Reported May 9
    		$-3.36$-3.54+5.08%Beat-1.2%
    Dec 21
    Reported Feb 24
    		$-3.78$-3.88+2.58%Beat+1.0%
    Sep 21
    Reported Nov 4
    		$-3.79$-3.85+1.56%Beat-1.1%
    Jun 21
    Reported Aug 5
    		$-3.72$-3.54-5.08%Miss-17.0%
    Mar 21
    Reported May 6
    		$-3.32$-3.94+15.74%Beat-41.9%
    Dec 20
    Reported Feb 25
    		$-3.82$-3.85+0.78%Beat-112.2%
    Sep 20
    Reported Nov 5
    		$-3.75$-3.30-13.64%Miss-169.8%
    Jun 20
    Reported Aug 6
    		$-3.18$-2.43-30.86%Miss-148.4%
    Mar 20
    Reported May 7
    		$-2.34$-1.95-20.00%Miss-138.8%
    Dec 19
    Reported Feb 26
    		$-1.80$-1.65-9.09%Miss-140.0%
    Sep 19
    Reported Nov 6
    		$-1.39$-1.42+2.11%Beat-148.2%
    Jun 19
    Reported Aug 7
    		$-1.28$-1.22-4.92%Miss-184.4%
    Mar 19
    Reported May 8
    		$-0.98$-0.97-1.03%Miss-117.8%
    Dec 18
    Reported Feb 27
    		$-0.75$-0.74-1.35%Miss-11.9%
    Sep 18
    Reported Nov 6
    		$-0.56$-0.53-5.66%Miss+17.6%
    Jun 18
    Reported Aug 7
    		$-0.45$-0.62+27.42%Beat+34.8%
    Mar 18
    Reported May 8
    		$-0.45$-0.77+41.56%Beat+10.0%
    Dec 17
    Reported Mar 13
    		$-0.67$-0.70+4.29%Beat+0.0%
    Sep 17
    Reported Nov 9
    		$-0.68$-0.79+13.92%Beat+57.2%
    Jun 17
    Reported Aug 10
    		$-0.69$-0.60-15.00%Miss-
    Mar 17
    Reported Apr 3
    		$-0.50$-0.87+42.53%Beat-
    Dec 16
    Reported Mar 31
    		$-0.67N/A+51.80%Beat-
    Sep 16
    Reported Nov 14
    		$-1.59$-0.35-354.29%Miss-

    Key Metrics

    Valuation
    P/E Ratio-48.91EV/EBITDA-8.32x
    Price/FCF-75.04xFCF Yield-1.33%
    Profitability
    Profit Margin-25.30%Operating Margin-15.50%
    ROE-53.30%ROIC-29.77%
    Financial Health
    Debt/Equity0.65xInterest Coverage-9.50x
    Current Ratio3.20xQuick Ratio2.94x
    Trading Statistics
    Beta-0.99Avg Volume229.91K
    52-Week High$615.0052-Week Low$393.61

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$540.08
    SMA 20$530.20
    SMA 50$530.33
    SMA 200$515.09
    EMA 10$537.20
    EMA 20$533.13
    EMA 50$526.81
    EMA 200$498.38

    MACD

    Line: 4.82Signal: 4.13Hist: 0.69

    ADX

    ADX: 10.1+DI: 21.5-DI: 20.8

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down28.0
    PSAR$552.08

    Bollinger Bands

    Upper Band$557.12
    Lower Band$503.27
    %B Position1016%(Upper)
    Band Width0.55

    RSI (14-Day)

    Neutral
    50.8

    Momentum Oscillators

    Stoch %K69.2
    Stoch %D72.1
    Williams %R-41.4
    ROC (10d)-1.1%
    Momentum-5.76
    CCI (20d)13.1
    MFI (14d)53.7

    Volatility Measures

    ATR (14d)$19.74(3.7%)
    StdDev (20d)13.46
    Hist Vol39.1%(Moderate)

    Volume Flow

    VWAP$531.78
    OBV899.3K
    AD Line5.5M
    CMF (20d)0.087

    Volume Metrics

    Avg Vol (20d)227.1K
    Vol Ratio1.0x
    VWMA (20d)$529.82

    Pivot Points

    R3$578.55
    R2$564.26
    R1$555.46
    Pivot Point$541.17
    S1$532.37
    S2$518.08
    S3$509.28

    Advanced Oscillators

    TSI6.95
    Ultimate Osc55.4
    KST23.47

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$364.25M$311.34M$321.08M$287.27M$212.80M$137.25M$103.32M$62.17M$14.64M$0$770,000$0
    Cost of Revenue$0$0$24.45M$0$0$0$3.44M$0$0$0$142,000$0
    Gross Profit$364.25M$311.34M$321.08M$287.27M$212.80M$137.25M$103.32M$62.17M$14.64M$0$-142,000$0
    Operating Expenses$420.56M$404.06M$380.69M$401.24M$260.00M$216.56M$170.32M$178.48M$177.18M$152.04M$117.18M$98.53M
    R&D$91.18M$108.69M$116.27M$174.00M$54.08M$44.17M$25.65M$68.74M$71.09M$71.24M$70.64M$70.95M
    SG&A$329.38M$295.37M$264.42M$227.24M$205.92M$172.39M$144.67M$109.74M$106.08M$80.80M$46.54M$27.58M
    Operating Income$-56,308,000$-92,723,000$-59,609,000$-113,975,000$-47,202,000$-79,311,000$-66,997,000$-116,304,000$-162,537,000$-152,037,000$-117,176,000$-98,534,000
    Interest Income$7.10M$8.24M$9.46M$10.31M$8.23M$9.37M$11.08M$13.02M$14.22M$8.33M$8.95M$3.30M
    Interest Expense$7.94M$7.82M$8.30M$10.23M$3.26M$3.30M$3.50M$3.68M$3.66M$3.84M$3.97M$3.50M
    Income Before Tax$-57,939,000$-94,391,000$-58,575,000$-114,190,000$-42,281,000$-73,238,000$-59,416,000$-106,964,000$-151,971,000$-147,541,000$-112,194,000$-98,740,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-57,939,000$-94,391,000$-58,575,000$-114,190,000$-42,281,000$-73,238,000$-59,416,000$-106,964,000$-151,971,000$-147,541,000$-112,194,000$-98,740,000
    EBITDA$-55,613,000$-93,572,000$-57,201,000$-112,030,000$-46,441,000$-78,440,000$-66,094,000$-115,984,000$-161,798,000$-151,214,000$-116,281,000$-97,725,000
    EBIT$-57,103,000$-94,815,000$-59,609,000$-114,268,000$-47,244,000$-79,311,000$-66,997,000$-116,304,000$-162,537,000$-152,037,000$-117,176,000$-98,534,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MDGL

    Government Contracts

    Gov Obligations (TTM)
    $65309
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    2
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24526N0482Department of Veterans AffairsDepartment of Veterans Affairs$35623Apr 3, 2026
    36C24526N0629Department of Veterans AffairsDepartment of Veterans Affairs$29686Jun 5, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

    Institutional investors are significantly invested in Madrigal Pharmaceuticals (MDGL), owning over 95% of its float, despite a recent stock dip. The company's drug Rezdiffra, the first FDA-approved treatment for MASH, is seeing rising sales even with competition from Novo Nordisk's Wegovy, as the MASH patient population is projected to grow substantially. Madrigal is also viewed as a strong takeover candidate due to Rezdiffra's patent protection, solid cash reserves, and a growing biotech M&A landscape.

    Yahoo Finance•9/10/26•
    Neutral

    Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference

    Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced its participation in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:00 P.M. EDT. The company, focused on therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), will webcast its presentation live. Madrigal's medication, Rezdiffra, is the first approved treatment for MASH with moderate to advanced fibrosis.

    The Manila Times•9/2/26•
    Neutral

    Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference

    Madrigal Pharmaceuticals, Inc. announced its participation in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:00 P.M. EDT. The biopharmaceutical company, focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its approved medication Rezdiffra, will webcast its presentation live. A replay will be available following the event.

    Yahoo Finance•9/2/26•
    Neutral

    When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable?

    This article analyzes Madrigal Pharmaceuticals, Inc.'s path to profitability. It will likely delve into financial forecasts, analyst expectations, and key milestones that could impact the company's future financial performance and when it might achieve profitability.

    富途牛牛•8/22/26•
    Neutral

    Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade

    An officer at Madrigal Pharmaceuticals, Inc. (MDGL), Shannon Kelley, plans to sell 664 shares of common stock valued at $337,019.84. This "sell-to-cover" transaction is intended to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on August 17, 2026, and is not a discretionary sale. The transaction was disclosed via a Rule 144 notice filed on August 20, 2026.

    Stock Titan•8/21/26•
    Neutral

    Frequently Asked Questions About MDGL

    Does MDGL pay dividends?
    Madrigal Pharmaceuticals Inc (MDGL) does not currently pay a regular dividend.
    What is MDGL's market cap?
    Madrigal Pharmaceuticals Inc (MDGL) has a market capitalization of $12.34B with a current stock price of $533.12.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In